Accelrys employees can let out a collective "phew." Their company has extended its "long-standing" customer relationship with Pfizer, meaning the San Diego-based scientific software provider will keep getting business from one of the largest drugmakers in the world.
Scientific software maker Accelrys grew revenue to $41.6 million in the most recent quarter and kept pushing to become a platform for drugmakers and other R&D operations to manage and share lab data.
Certara has struck a deal to scoop up Simcyp, a maker of modeling software for preclinical drug research, in a move that expands the breath of its technology offerings to drug developers. The deal is...
Protein misfolding has been implicated in many different diseases ranging from certain forms of Lou Gehrig's disease and Alzheimer's to cancer. Now a research group hopes that its algorithm...
As reported here Tuesday, Accelrys ($ACCL), one of the world's biggest providers of R&D software, has expanded into the quality control arena with its $35 million buyout of VelQuest. And the
With its R&D software facing lots of competition, Accelrys ($ACCL) made a move announced today to expand its menu of applications into the drug-manufacturing arena. The San Diego-based company is
Amsterdam-based information products giant Elsevier has gobbled up Ariadne Genomics, a company that provides software allowing researchers to study molecular pathways and disease progression. With
The field of lab management software outfits just got smaller. Israel-based BioData has gobbled up the assets of struggling rival LabLife, a Cambridge, MA, firm that had gained thousands of
With the new release of its key life sciences modeling and simulation software, Accelrys ($ACCL) has added algorithms licensed from MIT that were developed to aid in the design of biologic drugs such
Symyx (Nasdaq: SMMX) has unveiled a hosted informatics service that combines the company's software with data archiving capabilities in a secure data hosting and communications facility. The SaaS